These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2849975)

  • 21. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
    Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM
    J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of clusterin in human breast carcinoma.
    Redondo M; Villar E; Torres-Muñoz J; Tellez T; Morell M; Petito CK
    Am J Pathol; 2000 Aug; 157(2):393-9. PubMed ID: 10934144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vimentin expression in benign and malignant breast epithelium.
    Heatley M; Whiteside C; Maxwell P; Toner P
    J Clin Pathol; 1993 May; 46(5):441-5. PubMed ID: 7686566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.
    Travis A; Pinder SE; Robertson JF; Bell JA; Wencyk P; Gullick WJ; Nicholson RI; Poller DN; Blamey RW; Elston CW; Ellis IO
    Br J Cancer; 1996 Jul; 74(2):229-33. PubMed ID: 8688326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast.
    Looi LM; Cheah PL; Zhao W; Ng MH; Yip CH
    Malays J Pathol; 2006 Dec; 28(2):83-6. PubMed ID: 18376796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of the in situ component in 389 infiltrating ductal breast carcinomas.
    Carabias-Meseguer P; Zapardiel I; Cusidó-Gimferrer M; Godoy-Tundidor S; Tresserra-Casas F; Rodriguez-García I; Fábregas-Xauradó R; Xercavins-Montosa J
    Breast Cancer; 2013 Jul; 20(3):213-7. PubMed ID: 22271067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of glycodelin protein and mRNA in human ductal breast cancer carcinoma in situ, invasive ductal carcinomas, their lymph node and distant metastases, and ductal carcinomas with recurrence.
    Jeschke U; Mylonas I; Kunert-Keil C; Dazert E; Shabani N; Werling M; Kuhn C; Janni W; Gerber B; Friese K
    Oncol Rep; 2005 Mar; 13(3):413-9. PubMed ID: 15706409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunohistochemical analysis of overexpression of c-erbB-2 protein in node-positive breast carcinoma].
    Maeda S; Watatani M; Nagayama K; Kadota K; Ozaki K; Wada T; Yasutomi M
    Nihon Geka Gakkai Zasshi; 1993 Jan; 94(1):86-92. PubMed ID: 8094884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer.
    Walker RA; Gullick WJ; Varley JM
    Br J Cancer; 1989 Sep; 60(3):426-9. PubMed ID: 2571356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
    Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
    Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential.
    Bevilacqua G; Sobel ME; Liotta LA; Steeg PS
    Cancer Res; 1989 Sep; 49(18):5185-90. PubMed ID: 2475243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma.
    Naber SP; Tsutsumi Y; Yin S; Zolnay SA; Mobtaker H; Marks PJ; McKenzie SJ; DeLellis RA; Wolfe HJ
    Am J Clin Pathol; 1990 Aug; 94(2):125-36. PubMed ID: 1973590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast.
    Mariani-Costantini R; Escot C; Theillet C; Gentile A; Merlo G; Lidereau R; Callahan R
    Cancer Res; 1988 Jan; 48(1):199-205. PubMed ID: 2825967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma--a detailed morphological analysis.
    Ramachandra S; Machin L; Ashley S; Monaghan P; Gusterson BA
    J Pathol; 1990 May; 161(1):7-14. PubMed ID: 1973459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor].
    Manavi M; Czerwenka KF; Zeillinger R; Speiser P; Kury F; Steinhart U; Peschke M; Kubista E; Reinold E
    Zentralbl Gynakol; 1992; 114(2):82-5. PubMed ID: 1350129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.